23EL-810 On-Demand eCast: Whole Blood Vs. Components Vs. Crystalloid: What’s The Evidence?

Credits
1.5 General Continuing Education (GEN) | 1.5 Florida Lab Personnel (FLP) | 1.5 California Nurse (CN) | 1.5 California Lab Personnel (CLP) | 1.5 Physician (PHY)

Live Program Date: Wednesday, March 1, 2023
Program Number: 22EL-810

Educational Track: Technical/Clinical
Topic: Blood Donation & Collection, Patient Transfusion
Intended Audience: CEOs, CFOs, COOs, Directors, Hospital Blood Banks, Hospitals, Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Residents/Fellows, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
Teaching Level: Advanced, Basic, Intermediate

Faculty
(titles and affiliations at the time of the live program)
Director/Moderator: Elizabeth St. Lezin, MD, Professor of Laboratory Medicine, Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA
Speakers: Mark Yazer, MD, Professor of Pathology, University of Pittsburgh, Pittsburgh, PA; Richard L. Haspel, MD, PhD, FRCPath(Hon), Professor of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA

Program Description
There has been growing interest in the use of massive transfusion protocols and whole blood for use in both trauma and non-trauma patients. Should these patients receive whole blood? This program will first review the latest literature on the prehospital resuscitation of trauma patients with massive hemorrhage. Second, the program will review the state of the evidence for the use of whole blood and component therapy in trauma and non-trauma patients. The purpose of the program is to aid transfusion services and blood banks in planning for the optimal support of bleeding patients in both trauma and non-trauma settings.

Learning Objectives
After participating in this educational activity, participants should be able to:

  • Analyze the current literature on the resuscitation of bleeding trauma patients using whole blood versus components versus crystalloid in the prehospital setting.
  • Describe the role of whole blood versus ratio-driven component therapy in trauma and non-trauma patients.
  • Apply existing evidence in deciding on the optimal support of bleeding patients in both trauma and non-trauma settings.

How to Claim Continuing Education Credit

  • Single Viewers: if you registered as a single viewer, complete the evaluation found on the "CE Information" tab after watching the video. By submitting the evaluation, you are attesting to watching the presentation in its entirety.
  • Group Viewers: This is applicable for groups/facilities that purchased Group Viewing access for this program (registration will be verified prior to processing a group viewing attendance log). Group Viewing Coordinators should submit the attendance log to eLearning@aabb.org within 72 hours of the completion/viewing date. Once AABB receives an attendance log, each participant on the attendance log will be granted access as a single viewer to this program and will be required to complete the evaluation in order to claim continuing education credit. Each participant will be required to have an AABB account in order to access this program/platform. If a participant does not have an account, he/she can create one using the same email address provided on the attendance log.

Director & Moderator

Speaker Image for Elizabeth St. Lezin
University of California San Francisco

Speakers

Speaker Image for Mark Yazer
University Pittsburgh
Speaker Image for Richard Haspel
Professor of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School

Related Products

Thumbnail for AM24-SN-14-O: Blood Donation, Race and Transfusion Medicine: Looking Back to Move Forward (Enduring)
AM24-SN-14-O: Blood Donation, Race and Transfusion Medicine: Looking Back to Move Forward (Enduring)
Race is a sociopolitical and not biological construct. As such, the use of race-based algorithms and disease associations has caused demonstrable harm such as delayed kidney transplant referral and missed diagnoses. The field of transfusion medicine is not immune…
Thumbnail for AM23-TU-02-O: Designing and Optimizing Massive Hemorrhage Protocols (Enduring)
AM23-TU-02-O: Designing and Optimizing Massive Hemorrhage Protocols (Enduring)
While massive transfusion protocols have been widely implemented for management of hemorrhaging patients, they vary in components and may not include an ongoing assessment process…